Skip to main content
Press Releases

Biome Diagnostics identifies tumor-agnostic biomarker for cancer immunotherapy in a new meta-analysis of microbiome studies

By November 2, 2021No Comments

Biome Diagnostics (BiomeDx) presents new meta-analysis which reinforces the significance of the intestinal microbiome as a valid biomarker for cancer immunotherapy.

VIENNA, November 2021: The Austrian MedTech company BiomeDx has dedicated its efforts to advance precision medicine and is pioneering the development of a biomarker for cancer immunotherapy based on the intestinal microbiome. In a recent poster BiomeDx presented a study-based meta-analysis of advanced non-small cell lung cancer (NSCLC) and melanoma patients that supports the potential of the human intestinal microbiome as a predictor for immune checkpoint inhibitor (ICI) response. The poster was exhibited at the 45th annual conference of the Austrian Society for Pneumology ( and 8th Theodor Escherich Symposium ( symposium). The results align with findings from published studies and associate the abundance of certain species of bacteria with ICI response while a distinct group of bacteria are proven to be more abundant in non-responders.

The development of ICI therapeutics has been a revolutionary milestone in the field of immuno-oncology. Especially, for patients with NSCLC or melanoma ICI treatment has been a game changer. ICIs have shown to improve response and overall survival rates compared to standard cytotoxic chemotherapy. Yet, for a considerable number of patients ICI therapy is either associated with severe immune related adverse effects – such as fatigue, nausea, vomiting, diarrhea, and dermatological reactions – or has limited to no benefit. For the treating doctors the need for a reliable prognostic biomarker is evident.

While the presented results clearly contribute to the existing pool of research the more remarkable finding is the ability to identify responders and non-responders independent of specific tumor types – in other words the biomarker developed by BiomeDx seems to be tumor agnostic.

If that proves to be accurate this single biomarker might be the key for a truly personalized cancer immunotherapy.